Endovasc was established in 1996 as a Business Dev

Endovasc was established in 1996 as a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's subsidiaries include: Liprostin, which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Nutraceutical Development which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product; and Prostent, a stent coating technology. 

Liprostin is the liposome-encapsulated form of prostaglandin E-1 (PGE-1). A naturally occurring hormone, prostaglandin E-1 has been shown to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. In 1983, the U.S. Food and Drug Administration (FDA) approved prostaglandin E-1 for the treatment of ductus arteriosis of Botalli in neonates. Thus, much of the preclinical and clinical development and toxicology regarding the drug itself is known. 

The liposomal formulation of PGE-1 changes the drug's dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. Liprostin has the potential to positively impact many areas of treatment, including: 

o Peripheral Arterial Occlusive Disease (Critical Limb Ischemia or Intermittent Claudication) 
o Post-myocardial infarction therapy 
o Ischemic ulcers 
o Critical limb salvage 
o Claudicants 
o Pulmonary Hypertension 
o Diabetic neuropathy 
o Arthritis 

Endovasc has developed and patented a stent coating, PROStent, comprised of a polymer and prostaglandin E-1 (PGE-1). This coating slowly releases the hormone PGE-1 which has several potent activities that counteract the insult brought about by the surgical placement of a metal stent in a blocked artery vessel. At the onset, PGE-1 acts to block the inflammatory activity that occurs in response to the invasive procedure by down-regulating the immune response. 

Endovasc maintains a vast number of collaborative arrangements with research institutes around the world, including University of Texas Health Science Center, Houston; Texas Heart Institute; Baylor College of Medicine, Houston; Stanford University, Palo Alto; University of Bologna, Bologna; University of Frankfurt, Germany; Armed Forces Institute Hospital, Wash. DC; and Kings College Hospital, London. 

Endovasc has entered into two joint venture agreements with TissueGen for the development of the "next generation" of drug-eluting stents which will be comprised of a biocompatible, biodegradable, Resorbable material. 

Diane Dottavio, Ph.D. (President, Chief Executive Officer and Director) 
Dr. Dottavio has over 15 years of diverse experience in molecular biology and biochemistry with 10 years in management. Dr. Dottavio has held positions with such prominent research and pharmaceutical companies as Novartis and Millenium Pharmaceuticals. Dr. Dottavio received her Ph.D. in Biochemistry from the University of Texas in Austin. She pursued postdoctoral studies at The University of Texas at Austin, University of California at San Diego, La Jolla Cancer Research Foundation, and the Roche Institute for Molecular Biology in Nutley, NJ.